Can tofacitinib/Shangjie be used to treat vitiligo?

As a JAK inhibitor, Tofacitinib is currently approved in many countries and regions around the world for mainly immune-related chronic inflammatory diseases, including moderately to severely active rheumatoid arthritis, psoriatic arthritis, ulcerative colitis (UC) and ankylosing spondylitis, etc. A common feature of these diseases is an abnormally active immune system, leading to long-term inflammation and tissue damage in the joints, digestive tract, or skin. Tofacitinib effectively reduces the inflammatory response by blocking the JAK-STAT signaling pathway, so it has shown good results in the treatment of these diseases.

As for vitiligo, it is not currently an official indication for tofacitinib. Vitiligo is an acquired depigmentation skin disease with complex causes related to the immune system, genetic factors, oxidative stress and other mechanisms. In recent years, some overseas academic studies have explored the potential value of JAK inhibitors in the treatment of vitiligo, believing that blocking related inflammatory pathways may help restore melanocyte function. However, most of these studies are early exploratory clinical or case reports and have not yet formed sufficient evidence-based evidence. Therefore, the application of tofacitinib in the treatment of vitiligo is still in the research stage.

It should be noted that although some patients have found improvement in skin pigmentation when using tofacitinib to treat other immune diseases, this situation is not sufficient as a basis for clinical promotion. Patients who blindly attempt to treat vitiligo with tofacitinib may not only be at risk for drug side effects, but may also suffer from inadequate disease management due to lack of monitoring.

In the future, if there are more high-quality clinical studies to verify the exact efficacy and safety of JAK inhibitors on vitiligo, it may promote the expansion of indications. However, at the current stage, tofacitinib has not been approved for the treatment of vitiligo, and patients should follow formal channels to avoid the risks caused by off-label use of drugs.

Reference materials:https://www.xeljanz.com/